a riskUnproven stem cell treatment

A cell preparation sold as a treatment for a condition it has not been shown to treat, usually paid for out of pocket and usually outside any approval process. The CDC's account of cancer treatment abroad names the same structure: treatments obtained abroad "may have no established benefit", placing the patient at risk both from complications and from delaying or forgoing an approved therapy at home.

Two papers set the shape of this subject and neither is about a distant country.

In 2016 Turner and Knoepfler examined internet marketing of unapproved stem cell interventions and found the practice, already familiar in countries with permissive regulation, being carried on widely by businesses based in the United States. Their conclusion was directed at regulators rather than at patients: the marketplace needed better oversight. The finding matters here because it undercuts the geographic framing. This is not a risk that begins at a border.

In 2017 the New England Journal of Medicine reported three patients who received intravitreal injections of autologous adipose-derived "stem cells" at one US clinic. Before the injection their best documented visual acuity ranged from 20/30 to 20/200. After it they had ocular hypertension, haemorrhagic retinopathy, vitreous haemorrhage, retinal detachment or a dislocated lens. At one year their acuity ranged from 20/200 to no light perception. Three patients is not an incidence. It is a demonstration that the downside is not a wasted fee.

Inference — the exposure here is unlike the rest of this section in one respect. Every other risk on these pages is a way a real treatment can go wrong. This one is a fee paid for a treatment with no demonstrated benefit, so the loss is certain at the moment of payment and the clinical harm is the tail on top of it. A patient who forgoes an approved therapy to pursue it loses a third thing that cannot be bought back.

The commercial pattern is consistent: a condition with poor conventional options, a cell preparation described by its source rather than by any tested mechanism, payment in advance, no control arm, and testimonials in place of published outcomes. The regulatory position varies by country and by preparation, and is carried on this site's rule record rather than asserted here.

As of 16 September 2026 no register counts how many people travel across a border for an unapproved cell treatment, what they pay, or what happens to them. The published record consists of marketplace surveys and case reports, and the case reports exist because the harm was severe enough to reach a specialist unit.